Zimrixby (rituximab-cdxx)

Where it stands

Zimrixby (rituximab-cdxx) is approved in the US. The records show an FDA approval on 2026-07-31 for Dr Reddys Labs Sa, under BLA761376. The product is listed as a biosimilar in injection form.

The records do not give the therapeutic area or the approved indication(s), so this analysis cannot say which conditions Zimrixby is cleared to treat. They also do not give the reference product, dosing, strengths, presentations or launch timing. The only milestone is the approval itself, and the records label it an official source.

Regulatory pathway and designations

The only designation recorded is Biosimilar. In the US, a biosimilar is a biologic approved through a Biologics License Application (BLA). Here the BLA number is 761376. The application must show that the product is highly similar to an FDA-licensed reference product, with no clinically meaningful differences in safety, purity and potency. The records do not describe the data package submitted for Zimrixby.

The four-letter suffix in the nonproprietary name (rituximab-cdxx) follows FDA's naming convention for biologics. It helps distinguish products and attribute safety reports to the right one. The records do not say whether Zimrixby has an interchangeability designation, so none should be assumed.

The CHMP opinion date is blank because the record is for the US region. No EU or European Commission milestones are listed, and the records say nothing about the product's status in Europe.

Safety and pharmacovigilance

The records contain no safety data, label warnings, REMS information or post-marketing commitments for Zimrixby, so this section cannot be assessed from them. Readers should consult the FDA-approved prescribing information once it is available.

What to watch

First, the approved label. It will show the indications, the reference product and whether any are excluded or carved out, for example because of exclusivity or patents. Second, any interchangeability designation, which the records do not mention.

Third, commercial and access steps that the records do not cover: US launch timing, any settlement or patent constraints, and payer or formulary positioning. Finally, post-marketing safety reporting once the product is in use, where the distinct suffix helps attribute adverse event reports. Any EU filing or opinion would be a separate regulatory event, and none is recorded.